title: Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
abstract: BACKGROUND
  Persistent anti-donor isoagglutinins after major ABO blood group incompatible hematopoietic stem cell transplantation may cause delayed red blood cell engraftment and post-transplant pure red cell aplasia.
  
  
  METHODS
  We investigated the effect of pretransplant anti-donor isoagglutinin reduction by in vivo absorption and/or plasmapheresis on the incidence of pure red cell aplasia and the time to red blood cell engraftment in 153 hematopoietic stem cell transplant recipients with major ABO incompatibility.
  
  
  RESULTS
  Twelve patients (8%) developed pure red cell aplasia, 3/98 (3%) with, and 9/55 (16%) without prior isoagglutinin reduction (p=0.009). Red blood cell engraftment was faster in patients with isoagglutinin reduction; in addition, peripheral blood hematopoietic stem cell transplantation, acute graft-versus-host disease, and younger age were associated with faster red blood cell engraftment in Cox regression analysis. In patients with pure red cell aplasia the mean red blood cell engraftment occurred after 225 days (p<0.001) and was associated with a simultaneous decrease of anti-donor isoagglutinins. Patients with pure red cell aplasia had higher pretransplant anti-donor isoagglutinin titers (p=0.001) and received more post-transplant red blood cell transfusions (p<0.001).
  
  
  CONCLUSIONS
  Following major ABO incompatible hematopoietic stem cell transplantation, pure red cell aplasia and delayed red blood cell engraftment depend on the levels of anti-donor isoagglutinins and are efficiently prevented by the pretransplant removal of these isoagglutinins. The benefits of reducing the time of transfusion-dependency and transfusion-associated risks must be carefully balanced against the potential side effects of isoagglutinin reduction.
authors.affiliation: Clinic for Hematology and Laboratory for Transplantation Immunology, Department of Internal Medicine, University Hospital, Zürich, Switzerland. georg.stuessi@usz.ch
authors.forename: Georg
authors.initials: G
authors.lastname: Stussi
authors.forename: Jörg
authors.initials: J
authors.lastname: Halter
authors.forename: Eveline
authors.initials: E
authors.lastname: Bucheli
authors.forename: Piero V
authors.initials: PV
authors.lastname: Valli
authors.forename: Lutz
authors.initials: L
authors.lastname: Seebach
authors.forename: Jürg
authors.initials: J
authors.lastname: Gmür
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
authors.forename: Urs
authors.initials: U
authors.lastname: Schanz
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.forename: Jörg D
authors.initials: JD
authors.lastname: Seebach
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000373:Agglutinins / Q000302:isolation & purification*; D001787:Blood Group Incompatibility; D002648:Child; D002675:Child, Preschool; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012010:Red-Cell Aplasia, Pure / Q000517:prevention & control*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000017:ABO Blood-Group System; D000373:Agglutinins